1. Scrip
  2. >>Business
  3. >>Earnings

Almirall On Alert As Lebrikizumab Approval Date Approaches

As Dermatology Sales Climb In Q1

 
• By Kevin Grogan

The Barcelona-based group is confident that Lilly-partnered lebrikizumab has the potential to become a best-in-class treatment for atopic dermatitis and take market share from Sanofi’s blockbuster Dupixent.

Almirall
• Source: Almirall

Almirall SA has posted a healthy set of financials for the first quarter ahead of expected EU approval for lebrikizumab, the investigational atopic dermatitis drug partnered with Eli Lilly and Company which is expected to be transformational for the Spanish dermatology specialist.

A regulatory decision is scheduled by the fourth quarter for the closely watched interleukin-13 inhibitor, which was submitted to the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.